NCT07557706PHASE1Recruiting

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

University of Alabama at Birmingham

Start Date

9/15/2025

Completion Date

12/31/2026

Summary

The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.

Eligibility Criteria

Age Range: 18 years to 80 years

Inclusion Criteria: * Diagnosis of idiopathic PD * Stable medication for at least 4 weeks prior to the study Exclusion Criteria: * Use of beta blockers * Sustained severe hypertension (\>/= 180/110 mmHg while seated) * Significant uncontrolled cardiac arrhythmia * Unstable angina * Congestive heart failure * History of myocardial infarction * History of seizures * Severe cognitive impairment * Pregnant women or women who are planning to become pregnant

Interventions

DEVICE

transcutaneous auricular vagus nerve stimulation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

PARKINSON DISEASE (Disorder)

Locations

Wellness, Health and Research Facility at UAB

Birmingham, Alabama 35209

United States